<img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=780280282443813&amp;ev=PageView&amp;noscript=1">
search

    Aptevo Therapeutics Inc.

    verified_userVerify Profile
    Companies » Health Care » Health Care Equipment & Services » Biotechnology

    About Aptevo Therapeutics Inc.

    Aptevo Therapeutics Inc. is a clinical-stage biotechnology company focused on developing novel oncology and hematology therapeutics to meaningfully improve patients’ lives. Aptevo has a commercial product, IXINITY® coagulation factor IX (recombinant), approved and marketed in the United States for the treatment of Hemophilia B, and a versatile core technology – the ADAPTIR™ modular protein technology platform capable of generating highly-differentiated bispecific antibodies with unique mechanisms of action to treat cancer and autoimmune diseases. Source

    At A Glance

    • CAPITAL RAISE STATUS
      Not Currently Raising
    • FILING TYPE
      Public
    • PLATFORM TYPE
      NASDAQ
    • RAISED AMOUNT
      $X,XXX,XXX
    • PRE-MONEY EVAULATION
      $X,XXX,XXX
    • SIC CODE
      2834
    • NIN CODE
      ####
    • LEADERSHIP
      Marvin L. White
    • FOUNDED
      2016
    • EMPLOYEES
      101-250
    • SECTOR
      Health Care Equipment & Services
    • SUBSECTOR
      Biotechnology

    Company Tags

    No articles found.

    Heska Corporation

    Heska Corporation

    Heska Corporation (NASDAQ: HSKA – News) manufactures, develops and sells advance...

    Heska Corporation (NASDAQ: HSKA – News) manuf...

    Filing Type:    PU
    Forward Pharma A/S

    Forward Pharma A/S

    Forward Pharma A/S is a Danish biopharmaceutical company that commenced developmen...

    Forward Pharma A/S is a Danish biopharmaceutica...

    Filing Type:    PU
    DarioHealth Corp.

    DarioHealth Corp.

    DarioHealth Corp. (NASDAQ: DRIO) is a leading global Digital Therapeutics (DTx) co...

    DarioHealth Corp. (NASDAQ: DRIO) is a leading g...

    Filing Type:    PU
    Global Cancer Technology, Inc

    Global Cancer Technology, Inc

    Global Cancer Technology (“GCT”) is an emerging medical technology company with nu...

    Global Cancer Technology (“GCT”) is an emerging...

    Amount Raised:    $82,711.00
    Fundraising Status:    EC
    Filing Type:    CF
    Chembio Diagnostics, Inc.

    Chembio Diagnostics, Inc.

    Chembio is a leading point-of-care diagnostics company focused on detecting and di...

    Chembio is a leading point-of-care diagnostics ...

    Filing Type:    PU
    Motus GI Holdings, Inc.

    Motus GI Holdings, Inc.

    Motus GI Holdings, Inc. is a medical technology company, with subsidiaries in the ...

    Motus GI Holdings, Inc. is a medical technology...

    Filing Type:    PU
    Celsion Corporation

    Celsion Corporation

    Celsion Corporation is a fully integrated biopharmaceutical company focused on dev...

    Celsion Corporation is a fully integrated bioph...

    Filing Type:    PU
    BeyondSpring, Inc.

    BeyondSpring, Inc.

    Headquartered in New York, BeyondSpring Inc. (BeyondSpring) is a global, clinical-...

    Headquartered in New York, BeyondSpring Inc. (B...

    Filing Type:    PU
    Immutep Limited

    Immutep Limited

    We are a biotechnology company developing novel immunotherapy treatments for cance...

    We are a biotechnology company developing novel...

    Filing Type:    PU
    Replimune Group, Inc.

    Replimune Group, Inc.

    Cancer is one of the most difficult diseases to treat. It is constantly changing, ...

    Cancer is one of the most difficult diseases to...

    Filing Type:    PU
    ProLung, Inc.

    ProLung, Inc.

    ProLung is a medical technology company specializing in innovative predictive anal...

    ProLung is a medical technology company special...

    Filing Type:    PU
    G1 Therapeutics, Inc.

    G1 Therapeutics, Inc.

    G1 Therapeutics, Inc., is a clinical-stage biopharmaceutical company focused on th...

    G1 Therapeutics, Inc., is a clinical-stage biop...

    Filing Type:    PU
    ©2026 National Investor Network. All Rights Reserved.